04 · 21 proprietary layers
Layer 17 of 21 · Action and continuity
ToxCast Therapy toxicity risk and tolerability.
Why it's needed
What toxicity or tolerability considerations may be relevant to the patient or therapy?
What it draws on
3 of 8 evidence domains.
What it produces
Structured toxicity and tolerability considerations for clinical review.
Why it's essential
Layer 17 of 21.
1 · What it does
What ToxCast does
The best option on paper is not always the right one for a particular person. ToxCast is intended to surface toxicity and tolerability considerations relevant to the patient and the therapies under discussion, including pharmacogenomic (PGx) information where the testing pathway includes it.
2 · Scientific question
The question it addresses
What toxicity or tolerability considerations may be relevant to the patient or therapy?
Intended function
Describe the actually implemented toxicity and tolerability evidence sources and patient factors used.
3 · Data inputs and required context
What it draws on
- 07 Patient factors
- 06 Treatment exposure
- 01 Molecular & genomic
Patient factors (age, organ function, symptoms), treatment history and pharmacogenomic results where reported.
4 · Scientific basis
The science behind it
Scientific basis
Tolerability considerations draw on drug labelling, organ function, comorbidities, co-medications and, for some drugs, inherited pharmacogenomic variants for which professional dosing guidelines exist. Pharmacogenomics is one of Twin's integrated analytical features.
5 · Output and evidence sources
What it produces
Main output
Structured toxicity and tolerability considerations for clinical review.
Output type
- Evidence-linked interpretation. Connects a finding to published or curated evidence, which has a source and a date.
- Clinical-context integration. Depends on clinical information supplied by the treating team.
6 · Why it\u2019s essential
How it powers the Twin
Adds tolerability context to the treatment-options section.
Report section
Capability
ExploreReview treatment-relevant evidence, resistance-related findings and potential trial matches.
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
Tolerability considerations and PGx findings, sourced, alongside the options being weighed.
Doctor & Clinical TeamPatients & caregivers
Side effects and quality of life are part of choosing a treatment.
Patient & Caregiver8 · Dependencies and limitations
Limitations
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Considerations cite their source; PGx findings state the gene, the guideline used (once confirmed) and the route's PGx scope.
10 · Claim boundary
What this layer does not establish
It does not determine dosing or predict whether a specific patient will experience a specific side effect.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process